Skip to content
Capsul News Capsul News
4 min read Trial Tuesday

Trial Tuesday: ADCs And Method Marks In Madrid

Two papers came out of Madrid. Pfizer’s antibody-drug conjugate (ADC) missed in Phase III lung cancer and is pointing to a second-line subgroup for partial credit, while GSK’s ovarian cancer ADC has a strong early answer and is promising the working in Phase III.

A vintage pocket watch, a white eraser and a sharpened pencil resting on sheets of squared paper covered in handwritten calculus.
Somewhere between the first step and the last, a good result has to turn up. Photo by Luka Savcic on Unsplash
Share Share Share Email

Read next

Milestone Monday: The Weekend Madrid Stood Up For Small Cell Lung Cancer

Watchdog Wednesday: In US vs. China, Who’s Divorcing Whom?